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Abstract
Huntington’s disease (HD) is a progressive polyglutamine disease that leads to a severe
striatal and layer-specific neuronal loss in the cerebral neo-and allocortex. As some of
the clinical symptoms (eg, oculomotor dysfunctions) suggested a degeneration of select
brainstem nuclei, we performed a systematic investigation of the brainstem of eight clini-
cally diagnosed and genetically confirmed HD patients. This post-mortem investigation
revealed a consistent neuronal loss in the substantia nigra, pontine nuclei, reticulotegmental
nucleus of the pons, superior and inferior olives, in the area of the excitatory burst neurons
for horizontal saccades, raphe interpositus nucleus and vestibular nuclei. Immunoreactive
intranuclear neuronal inclusions were present in all degenerated and apparently spared
brainstem nuclei and immunoreactive axonal inclusions were observed in all brainstem
fiber tracts of the HD patients. Degeneration of brainstem nuclei can account for a number
of less well-understood clinical HD symptoms (ie, cerebellar, oculomotor and vestibular
symptoms), while the formation of axonal aggregates may represent a crucial event in the
cascades of pathological events leading to neurodegeneration in HD.
INTRODUCTION
Huntington’s disease (HD) is an autosomal dominantly inherited,
progressive and currently untreatable polyglutamine or CAG-
repeat disease (10, 16, 17, 24, 31, 46, 49, 56, 62, 72, 76, 77, 81, 82,
85, 86). Clinically, HD presents with somatomotor (ie, chorea,
bradykinesia, dystonia, rigidity, dysarthria, dysphagia), oculomo-
tor and psychiatric symptoms, cognitive decline and often with a
severe weight loss (5, 16, 25–27, 34, 42, 44, 49, 51, 62, 63, 72, 76,
83, 85, 86). Macroscopic brain alterations in HD commonly
include atrophy of all cerebral lobes, reduction of cerebral white
matter, atrophy of the striatum and enlarged lateral ventricles
(3, 5, 15, 25–27, 39–41, 62, 63, 72, 73, 81–83). Although the
degenerative process of the HD brain is widespread, to date,
the severe neuronal loss in the striatum and the layer-specific
neurodegeneration in distinct areas of the cerebral neo- and
allocortex is considered as generally the hallmark of the
neuropathological changes (3, 5, 15, 25–27, 31, 35, 39–41, 47, 52,
62, 63, 72, 73, 81–83). Based on the worsening and topographical
spread of the degenerative process of the striatum, a neuro-
pathological HD grading system has been developed (81–83).
Some of the unexplained HD symptoms (eg, oculomotor dysfunc-
tions) as well as the previous, but widely forgotten assumptions
have suggested additional degeneration of select brainstem nuclei
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in HD and pointed to the necessity of detailed brainstem studies in
HD (5, 32, 34, 35, 41, 42, 44, 45, 62, 64, 81–83).
Located on chromosome 4p16.3, the HD gene harbors
meiotically unstable CAG-repeats which encode the pathogenic
mutated protein huntingtin (16, 17, 31, 46, 49, 51, 72, 73, 76, 78,
81, 85, 86). In symptomatic HD patients and asymptomatic
gene carriers, these CAG-repeats are expanded and lead to a
polyglutamine expansion in mutant huntingtin. The normal physi-
ological CAG-repeat sequences comprise six to 35 CAG triplets,
whereby sequences of 28 and more already behave instable during
meiosis and may be prone to potentially symptomatic mutations.
CAG-repeat sequences longer than 35 are considered pathologi-
cally expanded, 36 to 40 CAG-repeats lead to an incomplete
penetrance and expansions of 41 or more CAG-repeats to the
fully developed clinical picture of HD (16, 31, 46, 49, 51, 66, 72,
76, 81, 85, 86).
The subcellular neuronal localization of huntingtin is complex
and dynamic. It is normally associated with the Golgi complex and
mitochondria, localizes to microtubules and synaptic vesicles, is
believed to play an important role in embryogenic development,
gene transcription, regulation of axonal transport mechanisms,
anterograde and retrograde trafficking of vesicles and organelles,
as well as in transport of signaling and trophic factors (1, 17, 21,
31, 46, 66, 79, 81). As with other polyglutamine disease proteins,
mutant huntingtin tends to aggregate into insoluble neuronal
intranuclear inclusions (NI), which also contain components of
the intracellular machinery responsible for protein handling and
degrading of misfolded proteins (eg, ubiquitin, proteasome subu-
nits, chaperones) (2, 10, 14, 17, 19, 31, 36, 46–48, 65, 66, 73, 74,
77, 80, 81, 85, 86). Although these NI may be present in the
cerebral cortex and striatum of HD patients, their pathogenic role
in the demise of neurons still is uncertain (1, 2, 14, 17, 19, 22, 31,
36, 47, 48, 56, 72–74, 80, 81). Recently, we described the brain
distribution, neuronal localization and composition of neuropil
protein aggregates in another polyglutamine disease, the spino-
cerebellar ataxia type 3 (SCA3 or Machado-Joseph disease) (69).
Inspired by the enigmatic pathogenic role of NI in HD and our
recent SCA3 findings, we performed a systematic immunohisto-
chemical study of the brainstem of eight clinically diagnosed and
genetically confirmed HD patients and analyzed the presence,
distribution and localization of NI and neuropil aggregates in
brainstem nuclei or fiber tracts. The results of these analyses
were correlated with the pathoanatomical findings obtained upon
investigation of unconventional thick tissue sections through the
brainstem of these HD patients.
PATIENTS AND METHODS
Patients
We investigated the brainstem of eight clinically diagnosed and
genetically confirmed HD patients (age at death: 67.3 ± 11.3 years;
Tables 1 and 2) and of 14 control individuals without histories
of neurological or psychiatric diseases in their medical records
and no diagnostic abnormalities recognized on neuropathological
examination of their brain (eight females, six males; age at death:
61.6 ± 16.5 years) (Table 3). All of our HD patients suffered
from involuntary choreatic movements and progressive cognitive
decline (patients 1–8; Table 1). Seven showed a severe weight loss
(patients 1, 2, 4–8; Table 1), five had dysphagia (patients 1, 2, 4, 5,
Table 1. Overview of the Huntington’s disease (HD) patients studied.
Abbreviations: CAG = number of expanded CAG-repeats in the mutated HD allele; F = female; HD = Huntington’s disease; M = male; TI = time
interval between the last neurological investigation and death.
HD Patient Age Gender CAG TI Vonsattel grade Onset of initial HD symptoms Initial HD symtpoms Duration of HD
1 51 M 49 60 4 33 Personality changes 18
2 61 F 45 6 3 35 Chorea 26
3 64 M 41 3 2 55 Chorea 9
4 65 M 45 36 4 53 Ataxia 12
5 68 F 46 18 3 40 Cognitive decline 28
6 68 M 40 29 3 60 Cognitive decline 8
7 70 F 44 4 2 50 Chorea 20
8 91 M 42 72 2 55 Chorea 36
Patient number, age at death (years), gender, number of expanded CAG-repeats in the mutated HD allele, time interval between the last neurological
investigation and death (TI, months), Vonsattel grade of striatal atrophy, age at onset of initial HD symptoms (years), initial HD symptoms, duration
of HD (years).
Table 2. Disease symptoms of the Huntington’s disease (HD) patients
studied possibly related to brainstem damage.
Patient Disease symptoms
1 Broad-based gait, dysphagia, slowed horizontal saccades,
slowed and saccadic smooth pursuits
2 Broad-based gait, dysphagia
3 Broad-based gait, inability to start horizontal saccades
without initial head thrust
4 Ataxia, dysphagia
5 Dysphagia
6 Gait imbalance
7 Broad-based gait, gait imbalance, dysphagia, slowed and
saccadic smooth pursuits
8 —
Patient number, disease symptoms possibly related to brainstem
damage.
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7; Tables 1 and 2) and four had dysarthria (patients 1, 4, 3, 7;
Table 1). Oculomotor dysfunctions noticed in the medical records
of the HD patients included slowed horizontal saccades (patient 1;
Tables 1 and 2), saccadic smooth pursuits (patients 1 and 7;
Tables 1 and 2) and inability to start horizontal saccades without
an initial head thrust (patient 3; Tables 1 and 2). Symptoms indi-
cating dysfunction of the cerebellum and/or the precerebellar
brainstem nuclei included unsteady and broad-based gait (patients
1, 2, 3, 7; Tables 1 and 2), dysarthria (patients 1, 3, 7; Table 1),
slowed smooth pursuits (patients 1, 7; Tables 1 and 2), ataxia
(patient 4, Tables 1 and 2), gait imbalance (patients 6 and 7;
Tables 1 and 2) and impaired gait coordination (patient 6, Tables 1
and 2).
Genetical examination revealed the presence of pathologically
expanded CAG-repeats in the mutated HD allele of all HD patients
(Table 1) (16, 49, 51, 76).
The primary causes of death of our HD patients included
cachexia (patients 1, 2, 4, 8; Table 1), subdural hematoma (patient
3; Table 1), aspiration pneumonia (patients 5 and 7; Table 1), rup-
tured aortic aneurysm (patient 6; Table 1) and pneumonia (patient
7; Table 1).
Tissue preparation and treatment
The HD patients’ time interval between the last neurological
examination and death was 28.5 ± 26.2 months (Table 1). Autopsy
of the HD patients was performed within 10.9 ± 5.2 h and that of
the control individuals within 18.1 ± 4.8 h post-mortem (Table 3).
Neuropathological investigation of the brains of the HD patients
and control individuals was performed by an experienced
neuropathologist (WF den Dunnen). Along with macroscopical
investigations, routine neuropathological examination also
included assessment of thin brain tissue sections. After fixation in
a 4% aqueous formaldehyde solution, the 22 brains (eight HD
patients, 14 controls) were assessed macroscopically. A grade of
neuropathological severity of striatal degeneration was assigned to
the HD brains according to the Vonsattel grading system (Table 1)
(81–83). Tissue blocks of the lower brainstem were embedded in
polyethylene glycol (PEG 1000, Merck, Darmstadt, Germany)
(75) and cut into seven equidistant series of 100 μm thick hori-
zontal sections.
In each instance the first set of serial brainstem tissue sections
was stained for lipofuscin pigment (aldehyde-fuchsin) and Nissl
material (Darrow red) (3, 4, 61–64) and applied for neuroana-
tomical orientation and pathoanatomical assessment of nerve cell
loss in the HD patients (Table 4).
The pathoanatomical approach complements the routine
neuropathological examination of thin brain tissue sections in the
field of basic neuropathological research. Its application to uncon-
ventionally thick serial brain tissue sections allows the recognition
of subtle pathological changes and reveals more detailed informa-
tion with respect to the extent and severity of the pathological
processes of neurodegenerative diseases (57, 59, 62, 64). Patho-
anatomical examination of neuronal loss in the HD brainstems was
performed twice by U. Rüb and its extent was scored as not
discernible (–), marked (+) or severe (++) (Table 4). The second
assessment of neuronal loss was perfomed 6 months after the first
one and blinded to its results.
Table 3. Overview of the control individuals studied.
Control
individual
Age Gender Cause of death Post-mortem
delay
1 39 F Ulcerative colitis 12
2 39 F Arrhythmia 21
3 39 F Thrombotic embolism 16
4 52 F Cachexia 24
5 54 M Cardiac arrest 24
6 57 F Arrhythmia 8
7 59 M Arrhythmia 12
8 63 F Lymphoproliferative disease 18
9 65 F Cardiac arrest 24
10 66 M Lymphoma, Sepsis 20
11 76 M Urosepsis 19
12 84 M Myocardial infarction 20
13 84 M Myocardial infarction 17
14 86 F Bronchopneumonia 18
Number of control individual, age at death (years), gender (F = female;
M = male), cause of death, post-mortem delay (hours).
Table 4. Distribution and extent of neuronal loss in the lower brainstem of Huntington’s disease (HD) patients.
Abbreviations: EBR = area of the excitatory burst neurons for horizontal saccades; IO = inferior olive; LV = lateral vestibular nucleus; MV = medial
vestibular nucleus; PCRT = parvocellular reticular nucleus; PN = pontine nuclei; RIP = raphe interpositus nucleus; RTTG = reticulotegmental nucleus
of the pons; SNC = substantia nigra, compact part; SNR = substantia nigra, reticulate part; SO = superior olive; SUV = superior vestibular nucleus;
VII = facial nucleus.
Patient SNC SNR PN RTTG SUV EBR RIP SO VII PCRT LV MV IO
1 + + + + − ++ ++ ++ + + + + +
2 + + + + + ++ + ++ + + + + +
3 + + + + + + + ++ − − + + +
4 + + + + + ++ ++ ++ − − + + +
5 + + + + − + ++ + − − + + +
6 + + + + − + ++ + − − + + +
7 + + + + − ++ ++ ++ − − + + +
8 + + + + − ++ + ++ − + + + +
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In all HD patients and control individuals, the second set of
serial brainstem tissue sections was immunolabeled with an
antibody directed against the protein aggregation marker p62
(1:100, Santa Cruz, Dallas, TX, USA). The multifunctional protein
p62 participates in the intracellular trafficking, aggregation and
degradation of various neurodegenerative disease proteins and
is known to bind to abnormal nuclear and/or cytoplasmic neuro-
nal accumulations of the disease-specific proteins of various
neurodegenerative diseases (35, 36, 67–69). Pretreatment for
antigen retrieval before the application of the p62 antibody was
performed with 10 mM citrate buffer (pH 6.0) at 90°C for 30
minutes. Positive immunoreactions were visualized with a 3,3-
diaminobenzidine-tetra-HCl/H2O2 reaction (DAB, D5637 Sigma,
Taufkirchen, Germany) resulting in a brown staining. The p62-
immunolabeled tissue sections were counterstained for lipofuscin
pigment (aldehyde-fuchsin) and Nissl material (Darrow red) (3, 4,
61–64) and used for the detection of NI bodies. The evaluation of
NI in the HD brainstem nuclei was performed twice by U. Rüb and
scored as follows: NI not detectable and this after confirmative,
sequential assessments of a given brainstem nucleus (−), rare (+)
or many (++). The second assessment of the presence of NI was
performed 6 months after the first investigation and blinded to the
results of the first assessment.
In each instance the third set of serial brainstem tissue sections
was immunostained for GFAP to reveal reactive astrocytes.
Double immunostaining procedures were performed to identify
and examine the topographical and intra-axonal localization, as
well as composition of neuropil aggregates. The AT270 antibody
(1:4000, Thermo Scientific, Rockford, IL; USA), directed against
the neuronal cytoskeletal protein tau was used as axonal marker
(18, 71) and the anti-p62 antibody applied as marker for axonal
protein aggregates (37, 38, 67–69). Pretreatment for antigen
retrieval prior to the application of the p62 antibody was per-
formed with 10 mM citrate buffer (pH 6.0) at 90°C for 30 minutes.
Positive axonal immunostaining was visualized with SK4700
(Linaris, D-97877 Wertheim, Germany), resulting in a blue-grey
staining, and the p62 immunolabeling with 3,3-diaminobenzidine-
tetra-HCl/H2O2 (DAB, D5637 Sigma) resulting in a brown stain-
ing. The presence of p62-immunopositive axonal inclusions was
semi-quantitatively assessed by U. Rüb and M. Hentschel and
categorized as follows: axonal inclusions not detectable even after
a time period of 3 minutes of careful investigation of a given fiber
tract (−), or rare, or detectable after a time period of 3 minutes of
examination (+), many (++) (Table 5). The assessments of U. Rüb
and M. Hentschel were performed independently and blinded to
the results of each other.
Double immunofluorescence was also applied to investigate the
colocalization of the p62 shuttle protein with (i) the pathologically
altered disease protein huntingtin harboring an elongated
polyglutamin tract or (ii) ubiquitin in axonal aggregates. We
applied the 1C2 antibody (1:3000, Millipore, Billerica, CA, USA)
to confirm the presence of huntingtin with an expanded
polyglutamine sequence of more than 37 repeats in the axonal
aggregates and used an ubiquitin antibody (1:1000, Cell Signaling,
Danvers, MA, USA) to investigate their additional association
with the small degradation-related protein ubiquitin. Select
brainstem tissue sections of all HD patients were (i) incubated with
both the monoclonal mouse and polyclonal rabbit primary anti-
bodies for 20 h at room temperature; (ii) followed by secondary
incubation for 90 minutes with Alexa 488 (1:1000, Invitrogen,
Carlsbad, CA, USA) and CY3 conjugated secondary antibodies
(1:500, Jackson ImmunoResearch, West Grove, PA, USA); and
(iii) treated for 10 minutes with 0.06% sudan-black for quenching
of autofluorescence. The primary and secondary antibodies
were applied simultaneously (69, 78). Antigen retrieval for p62/
ubiquitin double immunostainings was performed as described
above. Retrieval for 1C2/p62 was performed with Tris/HCl pH 9 at
90–05°C for 30 minutes, followed by incubation in 100% formic
acid for 3 minutes at room temperature.
We investigated the reproducibility of the examination of the
presence of NI, occurrence of axonal p62 immunoreactive aggre-
gates in brainstem fiber tracts, and of brainstem neurodegeneration
in the HD patients by means of inter-rater and intra-rater reliabi-
lities and calculated the weighted kappa coefficient Κw (BiAS for
Windows, version 9.14, Epsilon, Darmstadt, Germany). In the case
of disagreement of the investigators, the final assessment of
neuronal loss, presence of NI and intra-axonal aggregates was
decided during a final consensus meeting. Kendall’s rank correla-
tion coefficient tau (τ) was applied to examine the correlation
between neuronal loss in brainstem nuclei of the HD patients and
Table 5. Distribution of p62-immunopositive protein aggregates in axons of brainstem fiber tracts of Huntington’s (HD) patients.
Abbreviations: CCT = central tegmental tract; CU = cuneate fascicle; DST = dorsal spinocerebellar tract; GR = gracile fascicle; ICP = inferior cerebellar
peduncle; LL = lateral lemniscus; MCP = medial cerebellar peduncle; ML = medial lemniscus; MLF = medial longitudinal fascicle; NSP = nigrostriatal
pathway; OCF = olivocerebellar fibers; PCF = pontocerebellar fibers; PYR = pyramidal tract; SCP = superior cerebellar peduncle; SOL = solitary tract;
SPV = spinal trigeminal tract; TZ = trapezoid body; VST = ventral spinocerebellar tract; III = oculomotor nerve; IV = trochlear nerve; V = trigeminal
nerve; VI = abducens nerve; VII = facial nerve; VIII = vestibulocochlear nerve; IX/X = vagal nerve; XII = hypoglossal nerve.
Patient III IV NSP MLF LL ML SCP V MCP PCF VI VII TZ CTT VIII ICP PYR SPV IX/X SOL OCF CU GR DST VST XII
1 + + ++ + + + ++ + + + + + + + ++ + + + + x + + + ++ ++ +
2 + + ++ + + + ++ + + + + + + ++ ++ + + + + + + + + + + +
3 + + ++ + + + + + + + + + + + + + + + + + + + + + + +
4 + + ++ + + + + + + ++ + + + ++ + + + + + + + + + + + +
5 + + ++ + + + + + + ++ + + + ++ + + + ++ + ++ ++ + + + + −
6 + + ++ + ++ + ++ + + + + + + + + + + + + + + + + ++ ++ +
7 + + ++ ++ ++ + + + + + + + + ++ + + + + + + + ++ ++ + + +
8 + + ++ + + + ++ ++ + + + ++ + ++ ++ + + ++ + + ++ + + + + +
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the length of the CAG-repeats in the mutated HD allele, age of HD
onset, duration of HD, age at death and the Vonsattel grade of
striatal atrophy (BiAS for Windows, version 9.14, Epsilon). The τ
coefficient was also used to describe the correlation between the
extent of neuronal loss in the brainstem nuclei of the HD patients
and the presence of p62 immunoreactive axonal inclusions in
associated brainstem fiber tracts (BiAS for Windows, version 9.14,
Epsilon).
Examination of the HD and control brainstems was approved by
the Ethical board of the Faculty of Medicine at the Goethe Uni-
versity of Frankfurt/Main.
RESULTS
The lower brainstem of all HD patients along with a flattened pons
showed no macroscopic signs of degeneration (Figure 1).
In contrast to the routine neuropathological examination per-
formed on thin tissue sections, our pathoanatomical study of thick
tissue sections revealed neurodegeneration of select brainstem
nuclei in all HD patients (Table 4).
A consistent neuronal loss was present in the dopaminergic
compact part and GABAergic reticulate part of the substantia nigra,
precerebellar pontine nuclei, reticulotegmental nucleus of the pons
(Figure 2A,B), inferior olive (Figure 3E,F), in the premotor oculo-
motor area of the excitatory burst neurons for horizontal saccades
(Figure 2C,D), raphe interpositus nucleus (Figure 2E,F), auditory
superior olive (Figure 3C,D), lateral and medial vestibular nuclei
(Figure 3A,B) Table 4). In addition, in a subset of our HD patients,
a mild neuronal loss was also present in the superior vestibular
nucleus, as well as in the ingestion-related facial and parvocellular
reticular nuclei (Table 4).
Calculation of Kendall’s rank correlation coefficient tau (τ)
revealed no significant correlation between neuronal loss in
brainstem nuclei and the length of the CAG-repeats in the mutated
HD allele, age of HD onset, duration of HD, age at death and
Vonsattel grade of striatal atrophy (allP-values > 0.10). Calculation
of the weighted kappa coefficient revealed a nearly perfect intra-
rater reliability for the semi-quantitative assessment of neuronal
loss in the brainstem nuclei of the HD patients (Κw = 0.83;
P < 0.0001).
No p62 immunoreactive nuclear inclusions (NI) were detected
within the brainstem of control brains. However, NI were found
within the brainstem of the eight HD patients. They involved both
the brainstem nuclei with or without documented neuronal loss.
The nucleus of a few neurons had two or even three NI (Figure 4).
Calculation of the weighted kappa coefficient revealed a nearly
perfect intrarater reliability for the semi-quantitative assessment of
p62 immunoreactive NI in brainstem nuclei of the HD patients
(Κw = 0.90; P < 0.0001).
Unlike in the control individuals studied, p62 immunoreactive
axonal inclusions were ubiquitous throughout the brainstem of all
HD patients (pyramidal tract, all cerebellar peduncles, medial
and lateral lemnisci, medial longitudinal fascicle, trapezoid body,
pontocerebellar and olivocerebellar fibers, pontine reticular forma-
tion, spinocerebellar tracts, cuneate and gracile fascicles) (Figure 5;
Table 5). Axonal inclusions were present in the axonal hillock
(Figure 5B) or in more distal parts of the axon (Figure 5A,C–
I,K,L,O,P) and in some instances occurred at multiple sites of an
affected axon (Figure 5J,M,N). Their shape varied from round
(Figure 5H,O), ovoid (Figure 5A,F,P), club-shaped (Figure 5B,
E,K,L), irregular (Figure 5C,D,J,M), ramified (Figure 5N), to
torpedo-like (Figure 5G,I). Their diameter was either nearly iden-
tical to that of the affected axon (Figure 5F,J,N) or larger than the
normal axonal diameter (Figure 5A–E,G–I,K–M,O,P). Calculation
of weighted kappa revealed a substantial interrater reliability for the
semi-quantitative assessment of p62 immunoreactive axonal inclu-
sions in brainstem fiber tracts (Κw = 0.74; P < 0.0001).
In contrast to the control cases studied, GFAP immunopositive
astroctyes were present in all degenerated and spared brainstem
nuclei of all HD patients (data not shown).
Additional double immunostainings of brainstem tissue sections
of our HD patients confirmed the presence of a protein with an
expanded polyglutamine stretch (ie, detection of mutant huntingtin
with the 1C2 antibody) in the p62-immunopositive axonal protein
aggregates (Figure 6) and also demonstrated their ubiquitination
(Figure 7).
DISCUSSION
Degeneration of the brainstem in HD
The degeneration of the brainstem and its possible clinical rel-
evance in HD has been controversially discussed in neuropatho-
logical research for many decades (5, 32, 45, 52, 62, 82, 83).
Neuropathological conjectures from years ago indicate that some
brainstem nuclei may undergo neuronal loss in HD (ie, dopa-
minergic and GABAergic substantia nigra, auditory superior olive,
lateral vestibular nucleus, precerebellar inferior olive), but these
earlier findings have not been revisited or taken into account by
current researchers. Thus, the involvement of the brainstem in
HD is not among the established degenerative features of HD (5,
32, 41, 52, 82, 83). Our present pathoanatomical study, performed
on serial thick tissue sections through the brainstem of eight
Figure 1. The lower brainstem in Huntington’s disease (HD). A. Ventral
aspect of the lower brainstem of a typical 76-year-old male control
individual (control individual 11; Table 3). B. The lower brainstem with
a flattened pons (asterisk) of a clinically diagnosed and genetically
confirmed female HD patient (onset of HD symptoms: 40 years; age at
death: 68 years; CAG-repeats in the mutated HD allele: 46; Vonsattel
grade of striatal atrophy: 3) (HD patient 5; Tables 1 and 2) (81–83).
Abbreviations: CP = cerebral peduncle; IO = inferior olive; MCP =
medial cerebellar peduncle; PYR = pyramidal tract; V = trigeminal nerve;
VI = abducens nerve; VII = facial nerve; VIII = Vestibulocochlear nerve.
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clinically diagnosed and genetically confirmed HD patients, con-
firms and extends the earlier assumptions regarding brainstem
involvement in HD. Based on our findings, damage to the
brainstem in HD proved to be more widespread than documented
so far in the published literature and included additional nuclei of
the precerebellar, vestibular, oculomotor and ingestion-related
systems. As degeneration of brainstem nuclei did not correlate
with the Vonsattel HD grade of striatal atrophy, it is likely that
damage to these nuclei does not develop simultaneously with, but
independently from the well-known pathognomonic lesions in
the striatum. Taken together, damage to the brainstem again shows
that neurodegeneration during HD is not restricted to the striatum
and cerebral neo- and allocortex. We conclude that HD is a
multisystem neurodegenerative disease (3, 5, 15, 25–27, 39–41,
73, 81–83) characterized by a distribution of brain damage that
shows more overlap with that of the polyglutamine ataxias (eg,
spinocerebellar ataxias types 1, 2, 3 and 7) than has been believed
(43, 54, 57–61, 70).
Clinicopathological correlation of brainstem
degeneration in HD
The human brainstem is integrated into various brain neurotrans-
mitter systems, as well as into circuits subserving auditory,
Figure 2. Neuronal loss in mid-pontine and pontomedullary nuclei in
Huntington’s disease (HD). A. Horizontal section through the mid-pons
of a representative 66-year-old male control individual depicting the
oculomotor reticulotegmental nucleus of the pons (RTTG) (control indi-
vidual 10; Table 3). B. Considerable neuronal loss in the RTTG of a
64-year-old male HD patient (CAG-repeats in the mutated HD allele:
41; age at HD onset: 55 years; duration of HD: 9 years; Vonsattel grade
of striatal atrophy: 2; patient 3; Tables 1, 2 and 4). Inset shows remaining
RTTG nerve cells and lipofuscin deposits in the neuropil (arrow).
C. Horizontal section through the caudal pons of a typical 54-year-old
male control individual depicting the area of the excitatory burst neurons
(arrowheads) for horizontal saccades (EBR) with its typical horizontally
oriented nerve cells (control individual 5; Table 3). D. Complete neuronal
loss in the EBR of a 51-year-old male HD patient (CAG-repeats in the
mutated HD allele: 49; age at HD onset: 33 years; duration of HD: 18
years; Vonsattel grade of striatal atrophy: 4; patient 1; Tables 1, 2 and 4).
E. Horizontal section through the pontomedullary junction of a 39-year-
old woman without any medical histories of neuropsychiatric diseases
showing the RIP with its typical omnipause neurons for saccades in all
directions (arrowheads) (control individual 3; Table 3). F. Severe loss of
RIP omnipause neurons of a 70-year-old female HD patient. Arrow
points to a surviving RIP nerve cell (CAG-repeats in the mutated HD
allele: 44; age at HD onset: 50 years; duration of HD: 20 years; Vonsattel
grade of striatal atrophy: 2; patient 7; Tables 1, 2 and 4) (A–F: aldehyde-
fuchsin Darrow red staining; 100 μm PEG sections).
Abbreviations: MLF = medial longitudinal fascicle; PNO = pontine
reticular nucleus, oral subnucleus; RIP = raphe interpositus nucleus;
VI = abducens nerve; VII = facial nerve.
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precerebellar, ingestion-related, and oculomotor functions, and
regulation of posture and balance (7, 9, 28, 29, 33, 58, 60, 64, 84).
Although a wide spectrum of oculomotor symptoms typically
emerge in HD patients (ie, slowed and saccadic smooth pursuits,
reduced gain of the vestibulo-ocular reflex and optokinetic
nystagmus, initiating deficits of saccades, slowing, restricted range
or loss of horizontally and/or vertical saccades; impaired steady
fixation) and may also occur in preclinical HD gene carriers (42,
44, 62), nearly all past attempts to decipher the morphological
counterparts of these oculomotor dysfunctions have failed (32, 45,
62). Progress in the field of the functional neuroanatomy of the
human oculomotor networks made over the last two decades led
to the identification and characterization of important premotor
oculomotor brainstem nuclei. As a result, a detailed and reliable
basis for precise structure-function relationships became avail-
able which enabled the establishment of clinicopathological
correlations in various neurodegenerative diseases (7, 9, 29, 58,
60, 62, 64).
Figure 3. Neuronal loss in the pontomedullary junction and medulla
oblongata in Huntington’s disease (HD). A. Horizontal section through
the pontomedullary junction of a typical 54-year-old male control indi-
vidual depicting the lateral (LV) and magnocellular portion of the medial
(MV) vestibular nuclei (control individual 5; Table 3). B. Severe loss of LV
and MV nerve cells of a 61-year-old female HD patient (CAG-repeats in
the mutated HD allele: 45; age at HD onset: 35 years; duration of HD: 26
years; Vonsattel grade of striatal atrophy: 3; patient 2; Tables 1, 2 and 4).
Arrow points to a remaining giant LV nerve cell. C. Horizontal section
through the mid-pons of a representative 54-year-old male control indi-
vidual depicting the auditory superior olive (SO) with its medial (MSO)
and lateral subnuclei (LSO) as well as its periolivary group (SOP) (control
individual 5; Table 3). D. SO neuronal loss of a 61-year-old female HD
patient (CAG-repeats in the mutated HD allele: 45; age at HD onset: 35
years; duration of HD: 26 years; Vonsattel grade of striatal atrophy: 3;
patient 2; Tables 1, 2 and 4) predominantly affecting the LSO and SOP.
E. Horizontal section through the medulla oblongata a 84-year-old male
control individual without any medical histories of neuropsychiatric dis-
eases showing the inferior olive (IO) with its principal (IOP) and medial
accessory subnuclei (IOM) (control individual 13; Table 3). F. Circum-
scribed severe neuronal loss in the IOP (asterisk) of an 91-year-old male
HD patient (CAG-repeats in the mutated HD allele: 42; age at HD onset:
55 years; duration of HD: 36 years; Vonsattel grade of striatal atrophy: 2;
patient 8; Tables 1, 2 and 4). Inset shows devastated area of the IOP
(marked in F by an asterisk) with severe neuronal loss and the presence
of extraneuronal lipofuscin deposits. Arrowheads point to remaining IOP
nerve cells and arrows to extraneuronal lipofuscin deposits which can
serve as reliable marker for neurodegeneration (A–F: aldehyde-fuchsin
Darrow red staining; 100 μm PEG sections).
Abbreviations: IO = inferior olive; IOM = inferior olive, medial accessory
subnucleus; IOP = inferior olive, principal subnucleus; LSO = lateral
superior olive; LV = lateral vestibular nucleus; MSO = medial superior
olive; MV = medial vestibular nucleus, magnocellular portion; SO =
superior olive; SOP = superior olive, periolivary group; TZ = trapezoid
body; VII = facial nerve.
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The raphe interpositus nucleus (RIP) (Figure 2E) was identified
and described in non-human primates and in humans 25 years ago.
This small nucleus at the midline of the pontomedullary junction
is located between the rootlets of the abducens nerve. The hori-
zontally oriented nerve cells of the RIP are linearly arranged
in a narrow band of only two or three nerve cells and represent
omnipause neurons that trigger the initiation of vertical and hori-
zontal saccades (7, 9, 29, 58, 62, 64). As the loss of omnipause
Figure 4. p62 immunoreactive neuronal intranuclear inclusions in
spared and degenerated brainstem nuclei in Huntington’s disease (HD).
P62 immumopositive neuronal intranuclear inclusions (NI) in well-
preserved brainstem nuclei in HD: A. pedunculopontine nucleus (PPT),
B. dorsal raphe nucleus (DR), C. locus coeruleus (LC), D. motor trigemi-
nal nucleus (MOV), E. gigantocellular reticular nucleus (GI), F. dorsal
motor vagal nucleus (DMV), G. hypoglossal nucleus (XII), H. external
cuneate nucleus (ECU). NI in degenerated brainstem nuclei in HD: I.
substantia nigra (SN), J. pontine nuclei (PN), K. reticulotegmental
nucleus of the pons (RTTG), L. facial nucleus (VII), M. superior olive (SO),
N. medial vestibular nucleus (MV), O. lateral vestibular nucleus (LV),
P. inferior olive (IO) (A, B, F, L, N, O: HD patient 1—Table 1, CAG-repeats
in the mutated HD allele: 49; age at HD onset: 33 years; duration of HD:
18 years; Vonsattel grade of striatal atrophy: 4; C, G, H, M: HD patient
7—Table 1, CAG-repeats in the mutated HD allele: 44; age at HD onset:
50 years; duration of HD: 20 years; Vonsattel grade of striatal atrophy 2:
D, I: HD patient 4—Table 1, CAG-repeats in the mutated HD allele: 45;
age at HD onset: 53 years; duration of HD: 12 years; Vonsattel grade
of striatal atrophy: 4; E, J, K, P: HD patient 6—Table 1, CAG-repeats
in the mutated HD allele: 40; age at HD onset: 60 years; duration
of HD: 8 years; Vonsattel grade of striatal atrophy: 3) (A–P: p62
immunohistochemistry, counterstaining with aldehyde-fuchsin Darrow
red; 100 μm PEG sections).
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neurons in the RIP has recently been shown to correlate with
slowing of saccades (7, 9, 29, 58, 62, 64), the severe damage to
the RIP of our HD patients most likely contributed to the slowing
of horizontal saccades observed in our and other HD patients
(Table 2) (42, 44, 45, 62, 64). The human premotor area of
the excitatory burst neurons for horizontal saccades (EBR)
(Figure 2C) was described only some years after the RIP. The EBR
is only of about 2.5 mm in width and 2 mm in height and is located
Figure 5. p62 immunoreactive axonal neuronal inclusions in brainstem
fiber tracts in Huntington’s disease (HD). P62 immumopositive axonal
neuronal inclusions in HD: (A) oculomotor nerve (III), (B) trochlear nerve
(IV), (C) pontocerebellar fibers (PCF), (D) PCF), (E) trigeminal nerve (V),
(F) facial nerve (VII), (G) trapezoid body (TZ), (H) vestibulocochlear nerve
(VIII), (I) inferior cerebellar peduncle (ICP), (J) intermediate reticular zone
(IRZ), (K) olivocerebellar fibers (OCF), (L) hypoglossal nerve (XII), (M)
hypoglossal nerve (XII), (N) cuneate fascicle (ECU ), (O) solitary tract
(SOL), (P) dorsal spinocerebellar tract (DST). (A–P: p62/AT270 double
immunohistochemistry; 100 μm PEG sections) (A, E, K, N: HD patient
4—Table 1, CAG-repeats in the mutated HD allele: 45; age at HD onset:
53 years; duration of HD: 12 years; Vonsattel grade of striatal atrophy: 4;
B, L, P: HD patient 8—Table 1, CAG-repeats in the mutated HD allele:
42; age at HD onset: 55 years; duration of HD: 36 years; Vonsattel grade
of striatal atrophy: 2; C, D, F, G, H: HD patient 2—Table 1, CAG-repeats
in the mutated HD allele: 45; age at HD onset: 35 years; duration of HD:
26 years; Vonsattel grade of striatal atrophy 3; I: HD patient 5—Table 1,
CAG-repeats in the mutated HD allele: 46; age at HD onset: 40 years;
duration of HD: 28 years; Vonsattel grade of striatal atrophy 3; J, O: HD
patient 6—Table 1, CAG-repeats in the mutated HD allele: 40; age at HD
onset: 60 years; duration of HD: 8 years; Vonsattel grade of striatal
atrophy: 3; M: HD patient 1—Table 1, CAG-repeats in the mutated HD
allele: 49; age at HD onset: 33 years; duration of HD: 18 years; Vonsattel
grade of striatal atrophy: 4).
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in the pontine reticular formation underneath the medial longitu-
dinal fascicle and the internal genu of the facial nerve (7, 9, 29, 62,
64). The neurons of the EBR are essential for the initiation and
generation of horizontal saccades (7, 9, 29, 62, 64). Accordingly,
damage to the EBR most likely can account for the initiation
deficits of horizontal saccades of our and other HD patients
(Table 2) (42, 44, 45, 62).
The medial, lateral and superior vestibular nuclei (Figure 3A)
via their descending spinal projections are crucial for the mainte-
nance of truncal and postural stability (8, 60, 64). Their involve-
ment in our HD patients may explain as to why our and other HD
patients suffered from gait, truncal and postural instability with
a tendency to fall (Table 2) (6, 20). Because these vestibular
nuclei are important building blocks of the oculomotor circuits
subserving the optokinetic nystagmus and vestibulo-ocular reac-
tion (8, 62, 64), damage to these nuclei contributes to the occur-
rence of this type of impaired eye movements in HD (42, 44, 45).
The reticulotegmental nucleus of the pons (RTTG) (Figure 2A)
is a crucial component of the brain neural circuit engaged in the
regulation and control of smooth pursuit eye movements (62–64).
Thus, together with the lesions in the interconnected fastigial
nucleus of the cerebellum (63), damage to the RTTG is well suited
to explain why slowed and saccadic smooth pursuits occurred in
our and other HD patients (Table 2) (42, 44, 45, 62).
The pontine nuclei and the inferior olive (Figure 3E) represent
important building blocks in the precerebellar neuronal circuits
and are intimately connected with the cerebellar hemispheres
(neo- or pontocerebellum: pontine nuclei and inferior olive),
vermal and paravermal regions of the cerebellum (vestibulo- or
archicerebellum, spino- or paleocerebellum: inferior olive), as well
as associated deep nuclei (ie, fastigial, globose, emboliform and
dentate nuclei) (4, 84). Loss of Purkinje cells in the cerebellar
cortex and degeneration of nerve cells in all four deep cerebellar
nuclei of HD patients (63) in combination with neuronal loss in the
precerebellar pontine nuclei and inferior olive are detrimental to
the functions accomplished by the precerebellar and cerebellar
neural circuits and most likely contributed substantially to the
cerebellar disease symtoms observed in our and other HD patients
(ie, impairments of rapid alternating movements and fine
motor skills, dysarthria, hypotonia, postural instability and ataxia,
impaired gait balance, broad-based gait and stance) (Table 2)
(34, 49, 63, 85, 86).
Figure 6. p62 and 1C2 double
immunofluorescence of axonal inclusions in
brainstem fiber tracts in Huntington’s
disease (HD). Double immunofluorescence
of intra-axonal neuronal inclusions in the
nigrostriatal pathway (A–C) and (D–F)
pontocerebellar fibers of a representative
51-year-old male HD patient (CAG-repeats in
the mutated HD allele: 49; age at HD onset:
33 years; duration of HD: 18 years; Vonsattel
grade of striatal atrophy: 4; patient 1;
Tables 1, 2 and 5). Immunolabeling with
(A,D) an antibody against the proteasomal
shuttle protein p62 (red) and (B,E) the
anti-polyglutamine marker 1C2 (green).
The positive immunoreactions for the
anti-polyglutamine marker 1C2 point to the
recruitment of the pathologically altered
form of the disease protein huntingtin with
an elongated polyglutamine stretch into
the p62 immunoreactive axonal inclusions
(A, D: p62 immunostaining—Cy3; B, E: anti-
polyglutamine 1C2 immunostaining—Alexa
488; 100 μm PEG sections).
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The superior olive is located in the caudal pontine tegmentum,
embedded into the trapezoid body and involved in the performance
of auditory functions, such as perception of the temporal patterns
of sounds and analysis of the spatial attributes of sound sources (ie,
location, distance and movement) (Figure 3C) (28, 50). Accord-
ingly, the severe and consistent involvement of the superior olive
in our HD patients suggests that impairment of these auditory
functions may be among the disease symptoms of HD patients.
In view of the striking discrepancy between the involvement of
the superior olive in this study and missing clinical reports of
auditory impairments in our and other HD patients, additional
clinicopathological HD studies are required.
Degeneration of the dopaminergic compact part of the
substantia nigra is a characteristic and unifying neuropathological
hallmark of all clinical syndromes associated with parkinsonian
features (eg, Parkinson’s disease, progressive supranuclear palsy,
multiple system atrophy, corticobasal degeneration) (13, 23).
Although our study confirms a consistent loss of nerve cells of the
compact and reticulate parts of substantia nigra in HD (39, 41, 52),
the severity and extent of the neuronal loss in the compact part of
the substantia nigra may not suffice to provoke clinically relevant
parkinsonian features in adult HD patients (12, 53). This point
of view is in agreement with the clinical experience that parkin-
sonian extrapyramidal motor features (eg, rigidity) only emerge in
juvenile onset HD patients (82, 85, 86).
Neuronal intranuclear and axonal inclusions
and their possible significance to the
neurodegenerative process of HD
The aggregation of the disease protein huntingtin into NI bodies is
a well-known neuropathological feature of HD (3, 17, 19, 21, 22,
31, 36, 47, 48). NI are most frequent in the degenerated striatum
and cerebral neo- and allocortex and may contain components of
the cellular protein quality control machinery responsible for
removing and degrading structurally abnormal, misfolded and
ubiquitin-tagged proteins (ie, ubiquitin, chaperones, proteasome
subunits) (2, 17, 19, 21, 22, 30, 31, 47, 48, 55, 65, 74, 80). It is still
an open question whether NI are toxic to or protective for affected
nerve cells or merely represent pathognomonic morphological
hallmarks of HD and currently no idea is in existence with respect
to the possible mechanisms in which way they may contribute to
damage of affected nerve cells or facilitate their survival (17, 19,
31, 36, 65, 74, 80). In this study, we observed NI in neurons of all
brainstem nuclei of HD patients investigated, irrespective of
whether they showed signs of degeneration or appeared unaffected,
and failed to establish a correlation between the distribution of NI
and the pattern of neuronal loss in the brainstem. Evidently, our
correlative post-mortem approach cannot provide a conclusive
answer to the question whether the NI play a causal role in the
cascades of pathological events leading to nerve cell loss.
However, our study indicates that NI are to be considered as
pathognomonic morphological hallmarks of HD.
In addition, NI neuropathological studies also described the
occurrence of neuropil (ie, neuritic or axonal aggregates or swell-
ings) in select brain gray and white matters of HD patients (eg,
striatum, cerebral neocortex, internal capsule, cerebral peduncle)
(17, 22, 31, 36, 47, 65, 74). Our study represents the first system-
atic analysis of axonal protein aggregates in fiber tracts of a
Figure 7. p62 and anti-ubiquitin double immunofluorescence of axonal
inclusions in brainstem fiber tracts in Huntington’s disease (HD). (A–C)
Double immunofluorescence of intra-axonal neuronal inclusions in the
nigrostriatal pathway of a representative 64-year-old male HD patient
(CAG-repeats in the mutated HD allele: 41; age at HD onset: 55 years;
duration of HD: 9 years; Vonsattel grade of striatal atrophy: 2; patient 3;
Tables 1, 2 and 5) immunolabeled with (A) an antibody against the ubi-
quitin protein (green) and (B) the proteasomale shuttle protein p62 (red).
The presence of ubiquitin and p62 in intra-axonal aggregates (i) suggests
an involvement of the ubiquitin-proteasome pathway in the HD patho-
genesis and; (ii) points to defense mechanisms of affected nerve cells
that attempt to reduce levels of mutant huntingtin; but (iii) may also
reflect a decreased or compromised activity of the ubiquitin-proteasome
pathway or its overload in HD (A: p62 immunostaining—Alexa 488;
B: anti-ubiquitin immunostaining—Cy3; 100 μm PEG sections).
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coherent brain region of HD patients (ie, brainstem) and for the
first time demonstrates that axonal protein aggregations are a con-
sistent and widespread feature of brainstem pathology in HD.
Accordingly, together with SCA3, HD has now been recognized as
the second polyglutamine disease associated with the presence of
axonal protein aggregates (69, 70).
The composition of the intra-axonal inclusions observed
here shares many biological similarities with that of the NI.
Axonal inclusions in HD can be immunostained with the anti-
polyglutamine antibody 1C2 and along with the pathologically
altered form of the disease protein huntingtin with elongated
polyglutamin tract axonal inclusions in HD also contain the
degradation-related proteins p62 and ubiquitin. Together with
ubiquitin, p62 plays a central role in the highly dynamic pathways
that remove and degrade short-lived or aberrantly structured pro-
teins, thus preventing their aggregation (30, 55). Their presence in
intra-axonal aggregates of HD patients suggests an involvement of
the ubiquitin-proteasome pathway in the HD pathogenesis (10, 30,
84) and points to defense mechanisms of affected nerve cells
that attempt to reduce levels of mutant and misfolded huntingtin
(10, 17). The presence of ubiquitin and p62 in axonal aggregates
also reflects a decreased or compromised activity of the ubiquitin-
proteasome pathway or its overload in HD causing aggregate
formation (10, 30, 64, 80). Upregulation and enhancement of
proteasome activity with drugs is considered as a promising
therapeutical strategy to reduce the pathological levels of the
polyglutamine protein huntingtin and the pathological conse-
quences associated with this aggregation in affected nerve cells
(10, 30, 55).
Several disease models have proposed the occurrence and a
causative feature of axonal transport deficits in HD (11, 21).
Although the pathological mechanisms leading to axonal transport
deficits in HD remain unclear, it has been suggested that intra-
axonal transport deficits in HD may result from a physical block
caused by intra-axonal protein aggregation formation (11, 21). In
the present study, we could indeed observe intra-axonal protein
aggregates in the brainstem fiber tracts of the HD patients studied,
irrespective of the length, caliber or myelinization of the affected
axons. In view of their size, diameter and insolubility, these intra-
axonal aggregations are likely to physically block and to pertubate
anterograde and retrograde axonal transport processes (17, 21, 22,
31, 46, 65). The failure of anterograde transport mechanisms can
impair movement of protein complexes, synaptic vesicles and
neuronal organelles, can lead to structural changes in axons and
accumulations of vesicles and organelles (eg, mitochondria),
and can result in synaptic and mitochondrial dysfunction which
are detrimental to ATP production and energy metabolism further
impairing axonal transport processes (11, 17, 21, 31, 46, 63, 65).
In view of the current uncertainties regarding the mechanisms of
nerve cell death in HD and the possible consequences of intra-
axonal aggregates for neuronal viability or demise, we think it is
justified and worthwhile to perform additional HD studies aimed
to (i) reconstruct the spatial and temporal evolution of these axonal
aggregates and their association with the development of neuro-
degeneration; and (ii) to investigate the presence of axonal accu-
mulations of cellular organelles, vesicles and proteins in affected
axons. These future studies may help to decipher the pathophysi-
ological and pathobiochemical mechanisms of the neurodegene-
rative process of HD and represent a step forward on the road to a
causative and disease modifying therapy for this severe and disa-
bling human neuropsychiatric disease.
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